Literature DB >> 21103074

Prevalence of overactive bladder, its under-diagnosis, and risk factors in a male urologic veterans population.

Wellman W Cheung1, William Blank, Dorota Borawski, William Tran, Martin H Bluth.   

Abstract

PURPOSE: We assess the prevalence of overactive bladder (OAB) and its risk factors in a male urologic veterans population.
MATERIALS AND METHODS: Validated self-administered questionnaire was prospectively given.
RESULTS: Among 1086 patients, OAB was present in 75%, of which 48% had not been diagnosed/treated. The risk of OAB increased with age. OAB was not associated with BMI, smoking, race, diabetes, CHF, and COPD.
CONCLUSIONS: The prevalence of OAB in this population is under-diagnosed and under-treated.

Entities:  

Keywords:  OAB; incontinence; male; overactive bladder; urology; veterans

Mesh:

Year:  2010        PMID: 21103074      PMCID: PMC2990074          DOI: 10.7150/ijms.7.391

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


INTRODUCTION

Recent international population and non-population studies reported overactive bladder (OAB) in 10-17% of the adult population, depending on sex.1,2,3,4 In the U.S., a population-based study reported that 16.0% of men and 16.9% of women experienced OAB.5 No study has examined the prevalence of OAB in the urologic population, which is expected to be much higher. Some studies have reported association of OAB with age (men and women), body mass index - BMI (female), menopause (female), constipation (female), episiotomy (female), and beer consumption (men). 2, 6,7,8 In this prospective cohort study, we assess the prevalence of OAB in urologic male veterans population, the need for OAB screening, and risk factors for OAB.

METHODS

An IRB-approved self-administered questionnaire on urinary symptoms was given to male patients who visited the general urology outpatient clinic at a Veterans Administration hospital in Brooklyn, NY. It included questions on lower urinary tract symptoms (LUTS) with 0-5 point scale and on quality of life with 0-6 (best to worst) point scale (based on a modified validated Overactive Bladder 8-question Screener (OAB-V8)9). Questions on LUTS included urinary frequency (2 questions), urgency (2), nocturia (1), incontinence (2) and emptying (1). The questionnaire also included medical and surgical history, demographic data, BMI, medications and visit diagnosis. OAB-V8 total score that was equal to or greater than 6 for men was defined as OAB positive. Subsequent questionnaires from the same patient were excluded. To determine the relationship between OAB and other factors (age, BMI, smoking, race, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, diuretic medications and hepatitis), covariates were first individually evaluated using the chi-square test. Statistically significant (p < .05) covariates were retained for odds ratio analysis. Patients were excluded from a specific analysis if they did not report on the variable to be analyzed. Results are presented as odds ratio and 95% confidence interval (95% CI) 10. Statistical analyses were performed using Stata 8.2 (StataCorp, College Station, TX).

RESULTS

Among the male patients, 1086 completed the questionnaire. Table 1 summarizes the demographic data. Mean age was 68 years old (quartile range: 59-77). The major ethnicities were European American (44%), African American (37%) and Hispanic American (11%).
Table 1

Demographics

OAB was present in 75%. Among those surveyed with OAB, 48% had not been diagnosed with or treated for OAB, LUTS or benign prostatic hypertrophy (BPH). Those with OAB had a worse quality of life score. Mean quality of life score for those with OAB was 3.4 of 6, and those without OAB 1.6. Furthermore, 59% reported urge incontinence, 76% urgency, 90% frequency and 85% nocturia. There was no association of OAB with BMI (p=0.61), smoking (p=0.87), race (p=0.32), diabetes (p=0.83), hypertension (p=0.10), congestive heart failure (p=0.74), chronic obstructive pulmonary disease (p=0.69), and diuretic medications (p=0.91). The risk of OAB increased with age: 49% in men aged 40-49 years to 79% in men aged 70-79 years (p<0.001, OR=3.9). Interestingly, there was a statistically significant association between OAB and hepatitis (p=0.03, OR=2.2). See Table 3.
Table 3

Risk factors for OAB.

DISCUSSION

The prevalence of OAB in men has been reported to be 10.2-16.0%. It is expected to be much higher in the urologic setting since urinary complaint is a common reason for urologic visit. Our study found that 75% of those surveyed, experienced OAB. This is almost five fold higher than that reported for the general population. Since OAB is a compilation of lower urinary tract symptoms, the prevalence of LUTS should be higher. Irwin et al.2 in their 5-country population study reported the prevalence of any LUTS to be 62.5% whereas the prevalence of OAB to be 10.8%. Our study found that 95% reported urinary frequency and 85% nocturia. The increase in our study is consistent with Irwin et al.'s epidemiologic study. Although a higher prevalence of OAB is expected in our study population, the increase may also be compounded by variation in OAB definition. Most reported population studies had used the 2002 International Continence Society definition of OAB. Our study is based on a validated OAB screener questionnaire (OAB-V8). As with any screening tool, the sensitivity should be high but specificity may not be high. The OAB-V8 questionnaire has only been validated in a primary care setting. Validation in a high risk population is still pending. Our study showed that among those with OAB, only 52% had been diagnosed with or treated for urinary symptoms (OAB, LUTS and/or BPH). Furthermore, those with OAB had a worse quality of life score. Mean quality of life score for those with OAB was 3.4 of 6, and those without OAB 1.6. Thus, the 48% of men with OAB that are undiagnosed or untreated may benefit from better detection and treatment initiation. The OAB-V8 questionnaire is a possible effective and fast screening tool. Our study also examined the risk factors for OAB in men. We found that OAB increased with age: 49% in men aged 40-49 years to 79% in men aged 70-79 years (p<0.001, OR=3.9). This is consistent with previous epidemiologic studies. Our study also found an association between OAB and hepatitis (OR=2.2, p=0.03). It is uncertain how hepatitis relates to OAB. As such additional epidemiologic studies are needed in this regard. Unlike previous studies by Teleman et al.8, we found no association between OAB and BMI. However, patients in that study were all female. We also found no association with smoking, race, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and diuretic medications.

CONCLUSION

The prevalence of OAB in the male urologic veterans is almost five fold higher than that reported for the general population. OAB is under-diagnosed and under-treated. This patient population may benefit from routine screening. Furthermore, our study shows that OAB is associated with age and a history of hepatitis.
Table 2

Prevalence of OAB, LUTS and OAB subtypes.

  9 in total

1.  Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women.

Authors:  Wenju Zhang; Yanfeng Song; Xiaoyu He; Huijuan Huang; Bo Xu; Jian Song
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

2.  Prevalence of the overactive bladder syndrome by applying the International Continence Society definition.

Authors:  Christian Temml; Stefan Heidler; Anton Ponholzer; Stephan Madersbacher
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

3.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

4.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

5.  The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men.

Authors:  Helen M Dallosso; Ruth J Matthews; Catherine W McGrother; Madeleine M K Donaldson; Chris Shaw
Journal:  Public Health Nutr       Date:  2004-10       Impact factor: 4.022

6.  Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.

Authors:  Pia M Teleman; Jonas Lidfeldt; Christina Nerbrand; Göran Samsioe; Anders Mattiasson
Journal:  BJOG       Date:  2004-06       Impact factor: 6.531

7.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

8.  A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey.

Authors:  Sender Herschorn; Jerzy Gajewski; Jane Schulz; Jacques Corcos
Journal:  BJU Int       Date:  2007-10-01       Impact factor: 5.588

9.  Prevalence, evaluation and management of overactive bladder in primary care.

Authors:  Wellman W Cheung; Nadia H Khan; Karmina K Choi; Martin H Bluth; Miriam T Vincent
Journal:  BMC Fam Pract       Date:  2009-01-23       Impact factor: 2.497

  9 in total
  7 in total

Review 1.  Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.

Authors:  Kate McKeage
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

2.  Analysis of the prevalence and associated factors of overactive bladder in adult Korean men.

Authors:  So Young Kim; Woojin Bang; Hyo Geun Choi
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

3.  Replication of Mini-Sentinel Study Assessing Mirabegron and Cardiovascular Risk in Non-Mini-Sentinel Databases.

Authors:  Jason C Simeone; Beth L Nordstrom; Kwame Appenteng; Samuel Huse; Milbhor D'Silva
Journal:  Drugs Real World Outcomes       Date:  2018-03

4.  Overactive bladder in an integrated delivery system: a longitudinal cohort study.

Authors:  Jeffrey A Linder; Joel S Weissman; Harry Reyes Nieva; Stuart Lipsitz; R Sterling Haring; Julie DeAngelis; Rita M Kristy; Kevin R Loughlin
Journal:  BMC Health Serv Res       Date:  2020-05-20       Impact factor: 2.655

5.  Characterization of overactive bladder in women in a primary care setting.

Authors:  Wellman W Cheung; Dorota Borawski; Ovadia Abulafia; Miriam T Vincent; Miriam Harel; Martin H Bluth
Journal:  Open Access J Urol       Date:  2011-03-23

6.  Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder.

Authors:  L K Lee; A Goren; K H Zou; K Odell; D Russell; A L Araiza; X Luo
Journal:  Int J Clin Pract       Date:  2015-12-09       Impact factor: 2.503

7.  Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study.

Authors:  Hoon Choi; Jae Hyun Bae; Cheol Young Oh; Seong Jin Jeong; Woo Jin Ko; Jong Bo Choi; Ju Tae Seo; Dong Hwan Lee; Joon Chul Kim; Kwang Woo Lee; Young Ho Kim
Journal:  Int Neurourol J       Date:  2018-03-31       Impact factor: 2.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.